The company is working to develop and launch ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications including wet AMD, DME and BRVO. Outlook Therapeutics has entered into a strategic commercialization agreement with Cencora to expand reach for connecting to retina specialists and their patients.
Cyborg Score Rationale
The FDA issued a Complete Response Letter on August 29, 2023, acknowledging the NORSE TWO pivotal trial met safety and efficacy endpoints but concluding it could not approve the BLA due to manufacturing issues and lack of substantial evidence. The company faces significant regulatory and financial headwinds.
Top Insights
Market cap of approximately $34.8 million as of January 2026, indicating significant market skepticism
FDA Complete Response Letter represents major setback requiring manufacturing remediation and resubmission strategy
Company is working closely with FDA to address concerns with plans to request Type A meeting to discuss potential paths forward for approval
Clinical-stage status means no approved products and no meaningful commercial revenue
Named Competitors
Eylea (aflibercept) — Leading anti-VEGF for wet AMD and retinal diseases
Lucentis (ranibizumab) — Established anti-VEGF therapy for wet AMD
Avastin/Bevacizumab IV — Generic bevacizumab used off-label in retinal disease
Recent Developments
(August 2023) FDA issued Complete Response Letter rejecting BLA submission for ONS-5010
(January 2026) Stock trading near $0.42-0.54 range, down significantly from year highs
(February 2026) H.C. Wainwright lowered price target to $0.50
Open the full interactive Outlook Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.